Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

This year, drug companies have been living under a cloud of uncertainty created by the Trump administration. Threats of tough ...

The drugmaker's dividend streak is impressive, and the stock is trading at reasonable levels. 10 stocks we like better than Amgen › Generating passive income is great for investors, and holding ...

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts parsing the data presented at the American Diabetes Association annual meeting ...

Amgen (NASDAQ:AMGN – Get Free Report) ‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a research report issued on Tuesday, RTT News reports.

Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs ...